GV Research Platform

What GV Research Platform does

GV Research Platform (GVRP) is an integrated life sciences R&D platform and preclinical contract research organization (CRO) founded in 2020 and headquartered in Hyderabad, India. The company provides non-clinical research services including pharmacology, regulatory toxicology, safety assessment, analytical and bioanalytical testing, medical device biocompatibility testing (ISO 10993), immunogenicity studies, food and feed additive safety, and ecotoxicity assessment to pharmaceutical, biotechnology, medical device, agritech, and specialty chemicals clients. GVRP also distributes research products in India as an authorized partner of multiple international providers, including SPF research models and Teklad lab animal diets (Envigo), iPSC-derived cell lines (Nexel), primary hepatocytes (BeCytes), oncology screening platforms and PDX models (Crown Bioscience), the GARD sensitization assay suite (SenzaGen), humanized mice models (Biocytogen), and antibody discovery services (Yurogen).

The company operates from a 35,000 sq ft AAALAC International and OECD GLP-compliant flagship preclinical research center in Hyderabad's Genome Valley cluster, supported by a 2,000+ sq ft temperature/humidity-controlled warehouse for Teklad diet distribution and a 15,000 sq ft GSRC Centre of Excellence for formulations R&D jointly established with Steps Biosciences in Bengaluru's Lifescapes cluster in June 2026. Its subsidiary GV Safety Assessment Platform (GVSAP) focuses on safety assessment, and the company holds multiple sector accreditations including AAALAC International, OECD GLP, NGCMA GLP, NABL, ISO 9001:2015, CPCSEA, and ISO 10993 capability.

GVRP's business model combines project-based professional services revenue (CRO contracts with study-fee pricing) with distribution revenue from authorized resale of international research products. The go-to-market is direct enterprise field sales for services combined with channel/reseller distribution for products. The company serves 85+ clients with a team of 100+ members led by Co-Founder & CEO Kalyan Korisapati and CGO & Co-Founder Anirudh Srinivasan, supported by a Board-Certified Toxicologist (DABT/ERT) as VP. The platform integrates in-house expertise with seven international partnerships to provide single-point access to global research tools for the Indian ecosystem.

Name

GV Research Platform

Legal name

GV Research Platform

Website

https://gvrp.in

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

GV Research Platform is a Hyderabad-based preclinical contract research organization founded in 2020, providing GLP-compliant pharmacology, toxicology, safety assessment, and medical device testing services to pharmaceutical, biotech, medical device, and agritech clients across India, augmented by exclusive distribution of global research tools.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Laboratory Quality & GLP/GCLP Compliance (HLAGAKAK)

Keywords

• Preclinical contract research
• Toxicology testing services
• Safety assessment studies
• Bioanalytical testing services
• Laboratory research models

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services: Project-based preclinical research contracts providing pharmacology, toxicology, bioanalytical, and safety assessment services to pharmaceutical, biotech, medical device, agritech, and specialty chemicals companies. Revenue generated through study fees, with pricing based on study complexity, species, and regulatory requirements.
2. Research Products Distribution: Authorized distributor of international research products in India including SPF animal models (Envigo), Teklad® lab animal diets, iPSC-derived cell lines (Nexel), primary hepatocytes (BeCytes), and specialty assays. Products sold directly to research institutions and pharmaceutical companies.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Core offering

GVRP operates an integrated preclinical contract research organization (CRO) delivering non-clinical research services including pharmacology, regulatory toxicology, analytical and bioanalytical testing, safety assessment, immunogenicity studies, medical device biocompatibility testing (ISO 10993), and food/feed additive assessment. The platform also functions as an authorized India distributor for international research product lines including SPF rodent models, Teklad laboratory diets, iPSC-derived cell lines, primary hepatocytes, humanized mice models, oncology screening platforms, and genomic biomarker assays. Services are executed at two GLP-compliant facilities: a 35,000 sq ft flagship center in Hyderabad's Genome Valley and a 15,000 sq ft formulations R&D center in Bengaluru.

Product overview

GV Research Platform (GVRP) is an integrated life sciences R&D platform offering a comprehensive portfolio of preclinical research services and biological products. The core platform provides research services including Pharmacology, Analytical & Bioanalytical Testing, Regulatory Toxicology, and Safety Assessment, complemented by research products such as SPF Research Models, Biological Samples, and Teklad® Diets. GVRP extends its capabilities through exclusive partnerships with global technology providers: Crown Bioscience for oncology platforms (OmniScreen™ and MuScreen™); SenzaGen for the GARD® allergenicity assay suite; Yurogen Biosystems for antibody discovery; Nexel for iPSC-derived cells (Cardiosight®, Hepatosight®, Neurosight®); BeCytes for primary hepatocytes; Biocytogen for humanized mouse models; and Envigo for SPF models and Teklad® diets. The company operates R&D centers in Hyderabad (35,000 sq. ft.) and Bengaluru (15,000 sq. ft.), providing end-to-end solutions from early discovery through regulatory submission for pharmaceutical, biotechnology, medical device, and agrochemical industries.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmacology In vitro and in vivo pharmacology studies including high-throughput screening, mechanistic studies, disease-specific animal models, and customized study designs for efficacy and pharmacokinetic assessment. Targeted at pharmaceutical and biotechnology companies requiring preclinical efficacy data.
• Analytical & Bioanalytical Testing Method development and validation, bioanalysis, ADME/PK studies, dose formulation analysis, stability studies, and extractables/leachable analysis for pharmaceutical, biological, agrochemical, and medical device products. Targeted at developers requiring quantitative bioanalytical support for IND/NDA submissions.
• Regulatory Toxicology Comprehensive toxicology testing including exploratory and GLP-certified studies for pharmaceuticals, biologics, vaccines, agrochemicals, and medical devices, with regulatory submission support. Targeted at sponsors requiring IND-enabling and product registration toxicology data.
• Safety Assessment Preclinical safety evaluation including IND-enabling studies, in vivo toxicology, in vitro safety testing, and regulatory support for FDA, EMA, and global submissions. Targeted at pharmaceutical and biotechnology companies preparing global regulatory filings.
• Immunogenicity & Immunotoxicity Studies Comprehensive evaluation of immune responses to biologics, vaccines, and cell and gene therapies including immune organ analysis, cytokine profiling, and hypersensitivity assessments in preclinical models. Targeted at developers of biologics, vaccines, and advanced therapies requiring immunogenicity characterization for IND submissions.
• Medical Device Testing ISO 10993 biocompatibility testing services including cytotoxicity, sensitization, irritation, pyrogenicity, genotoxicity, implantation, and hemocompatibility for regulatory submissions to CDSCO, US FDA, and EU MDR. Targeted at medical device manufacturers (Class I, II, III) requiring biological safety evaluation for product registration.
• Food & Feed Additives Testing End-to-end preclinical assessment for food and feed additives including ingredient characterization, safety and toxicological evaluation, microbiological testing, and GLP-aligned study conduct. Targeted at food/feed additive and agritech companies requiring regulatory safety data.
• Ecotoxicity Assessment Services Environmental toxicity evaluation services for agrochemical and industrial chemical products including bioassays, field studies, and environmental fate modeling to support regulatory compliance. Targeted at agritech and specialty chemical companies needing ecotoxicity data for product registration.
• SPF Research Models SPF rodent models including immunocompromised strains (NOD scid, SCID beige, Athymic Nude) and traditional strains (C57BL/6, BALB/c, Sprague Dawley, Wistar Han, ICR), bred in partnership with Envigo RMS LLC under harmonized global standards. Targeted at pharmaceutical R&D and academic research institutions requiring reproducible animal models for preclinical studies.
• Biological Samples High-quality plasma, serum, and organ samples from validated rodent models (Sprague Dawley, Wistar Han, C57BL/6, Balb/c, athymic nude, SCID/beige, NOD.SCID) with custom tissue preparation options. Targeted at researchers needing validated biological matrices for assay development and bioanalysis.
• Teklad Laboratory Animal Diets Premium laboratory animal diets from Envigo (Teklad line) including rodent formulations 2014C (14% protein maintenance), 2018C (18% protein breeding and maintenance), autoclaved 2018SC, rabbit 2031C (high fibre), and guinea pig 2041C (Vitamin C fortified), distributed in India under temperature/humidity controlled warehousing with same-day dispatch. Targeted at animal research facilities and academic institutions across India.
• Human iPSC-Derived Cell Lines Nexel's iPSC-derived products including Cardiosight-S (cardiomyocytes), Hepatosight-S (hepatocytes), and Neurosight-S (neurons), distributed in India for drug discovery, toxicity testing, disease modeling, and regenerative medicine. Targeted at pharmaceutical R&D and academic researchers requiring validated human iPSC-derived cells.
• Primary Hepatocytes BeCytes Biotechnologies' primary human and animal hepatic cells including plateable and suspension hepatocytes, non-parenchymal cells (stellate cells, liver endothelial cells, Kupffer cells), and NASH hepatocytes, distributed in India. Targeted at ADME/PK researchers and pharmaceutical hepatotoxicity programs.
• Humanized Mice Models Biocytogen humanized mouse models including immune-checkpoint, cytokine, and GPCR models, plus engineered cell lines for preclinical drug evaluation, accessible through GVRP as the India channel partner. Targeted at immuno-oncology and infectious disease researchers in India.
• OmniScreen Oncology Screening Service Crown Bioscience's high-throughput oncology screening service for multiple drug compounds across diverse cancer cell line panels (OmniPanel 520+ lines, XenoSelect 210+ xenograft-bearing lines, PrimePanel 30+ primary PDX-derived lines) with integrated bioinformatics (dose-response curves, inhibition heat maps, RNAseq). Targeted at oncology drug developers seeking large-scale in vitro screening.
• MuScreen Immunotherapy Screening Crown Bioscience's in vivo immunotherapy screening platform using MuPrime syngeneic models and tumor homograft models for mechanism-of-action and efficacy evaluation in immunocompetent hosts. Targeted at immuno-oncology developers running preclinical immunotherapy efficacy studies.
• Oncology & Immuno-Oncology Drug Development Access to Crown Bioscience's comprehensive oncology services including in vitro platforms (2D cell lines, HuCell, CRISPR/Cas9 models, organoids) and in vivo pharmacology using PDX models, offered through GVRP in India. Targeted at oncology drug developers requiring PDX-based efficacy studies.
• Allergenicity Assessment (GARD Assay Suite) GARD assay suite from SenzaGen including GARDskin (OECD TG 442E approved for skin sensitization), GARDpotency (potency classification), GARDair (respiratory sensitization), and GARDskin Medical Device (ISO 10993 biocompatibility) using genomic biomarker signatures. Targeted at cosmetic, chemical, and medical device manufacturers needing in vitro alternative sensitization testing.
• Antibody Discovery Solutions Yurogen Biosystems' SMab single B-cell platform for antibody discovery from multiple host species (rabbit, mouse, human, camelid) including recombinant expression and SPR-based bioanalytical services. Targeted at biologics developers in India seeking advanced antibody discovery and engineering capabilities.

Quantifiable outcome

• India's bioeconomy exceeding USD 165 billion with 10,000+ biotech startups supports market opportunity for preclinical CRO services
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Ten partnerships are on record, tiered core.

• Steps BiosciencescoreStrategic or Co-development Partner · 4 June 2026Joint establishment of GSRC Center of Excellence for formulations research and development within the Lifescapes life sciences cluster in Bengaluru. Facility purpose-built to address complex formulation challenges including drug delivery systems, sterile injectables, and differentiated dosage forms. Represents GVRP's strategic expansion into high-complexity formulations.
• Yurogen BiosystemscoreStrategic or Co-development Partner · 20 February 2026Partnership to enhance biologics drug discovery in India. Yurogen provides advanced antibody discovery, engineering, and bioanalytical services using proprietary SMab™ single B-cell platform for antibody generation from multiple host species including rabbit, mouse, human, and camelid. GVRP enables researchers in India to access these services.
• BiocytogencoreStrategic or Co-development Partner · 5 February 2026Expanded strategic partnership between GV Safety Assessment Platform (GVSAP) and Biocytogen to enhance India's biopharma ecosystem. Strengthened alliance encompasses pharmaceutical services and licensing for gene-edited cell lines supporting research from target validation to pharmacological evaluation. CEOs of both companies highlighted partnership's role in facilitating precision-driven drug discovery in India's rapidly evolving biopharma sector.
• BeCytes BiotechnologiescoreChannel Partner/ Reseller/ Distributor · 3 February 2025Partnership to advance biopharma research in India through primary liver cell-based products. BeCytes (headquartered in Barcelona, Spain) specializes in human tissue procurement, cell isolation, and cell-based solutions for in vitro models. GVRP is authorized distributor for hepatic cell products including fresh and cryopreserved plateable human and animal hepatic cells.
• SenzaGencoreChannel Partner/ Reseller/ Distributor · 7 July 2023Partnership to transform safety assessment practices in India. GVRP authorized distributor of SenzaGen's GARD® assay suite including GARD®skin (OECD approved for skin sensitization), GARD®potency, GARD®air (respiratory sensitization), and GARD®skin Medical Device for ISO 10993 biocompatibility testing.
• NexelcoreChannel Partner/ Reseller/ Distributor · 22 March 2023Partnership to bring cutting-edge iPSC technology to India's biomedical community. Nexel (South Korea) manufactures iPSC-derived cardiomyocytes (Cardiosight®-S), hepatocytes (Hepatosight®-S), and neurocytes (Neurosight®-S) for drug discovery, toxicity testing, disease modeling, and regenerative medicine.
• Crown BiosciencecoreStrategic or Co-development Partner · 12 July 2022Partnership announced for Crown Bioscience services in India. Crown Bioscience is global CRO headquartered in San Diego with operations in 10 global locations. Expertise in oncology, immuno-oncology with tumor organoid services (HUB technology) and world's largest commercially available PDX collection.
• Envigo RMS LLC (Inotiv)coreChannel Partner/ Reseller/ Distributor · 30 May 2022Partnership for Indian market enabling access to Envigo research models. Envigo RMS LLC is a global leader in research model breeding and distribution providing high-quality branded models and Teklad® diets for preclinical research.
• Crown BiosciencecoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Crown Bioscience oncology services in India. Provides access to OmniScreen™ (high throughput oncology screening), MuScreen™ (in vivo immunotherapy screening), PDX models (world's largest collection), and Indivumed Services for biobank products and liquid biopsy samples.
• Envigo RMS LLC (Inotiv)coreChannel Partner/ Reseller/ DistributorExclusive breeding partner and authorized distributor of Envigo SPF research models in India. Provides access to branded Envigo research models including immunocompromised, traditional, and outbred rodent strains. Breeding program harmonized with Envigo global standards with veterinary team ensuring animal welfare and reproducibility.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Syngene International: Bengaluru-based, publicly listed integrated CRO/CDMO offering preclinical safety, toxicology, bioanalytical and formulation services to global pharma. Closest Indian peer to GVRP in service mix, regulatory credentials, and client base.
• Sai Life Sciences: Hyderabad-based contract research and manufacturing organization providing drug discovery, preclinical toxicology, and bioanalytical services. Direct competitor to GVRP in Indian preclinical safety assessment, headquartered in the same Genome Valley cluster.
• Piramal Pharma Solutions: India-headquartered CRO/CDMO with preclinical, analytical and manufacturing services. Overlaps with GVRP in safety assessment, bioanalytical testing and medical-device-related testing for global pharma sponsors.
• Anthem Biosciences: Bengaluru-based integrated CRO offering drug discovery, preclinical pharmacology and toxicology services. Direct Indian preclinical competitor with comparable therapeutic-area breadth and GLP capability.
• Bioneeds India: Bengaluru-based preclinical CRO specializing in GLP toxicology, safety pharmacology and medical device testing under OECD-GLP and AAALAC frameworks. Direct Indian niche competitor, especially for medical device biocompatibility work.
• Jubilant Biosys: Bengaluru-based discovery and preclinical CRO offering in vitro/in vivo pharmacology and toxicology services. Comparable in offering integrated discovery-through-preclinical solutions to global biopharma.
• Vivo Bio Tech: Hyderabad-based preclinical CRO offering toxicology, pharmacology and animal model services with OECD-GLP accreditation. Closely comparable Indian preclinical peer in scale, location and service profile.

Broad incumbents

• WuXi AppTec: China-based global CRO/CDMO with the largest preclinical and toxicology capacity in Asia. Comparable in preclinical service breadth but at vastly larger scale; competes for the same outsourcing-from-India sponsors.
• Charles River Laboratories: Global preclinical CRO leader offering toxicology, safety assessment, research models and bioanalytical services. Sets the global benchmark for GLP toxicology and is the principal incumbent GVRP competes against for Indian and global sponsor contracts.
• Labcorp Drug Development: Global CRO (formerly Covance) with extensive preclinical toxicology, bioanalytical and central-lab capabilities. Competes for the same global pharma preclinical outsourcing budgets that GVRP targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/gvrp_in
• Facebookfacebook.com/gvresearchplatform
• LinkedInlinkedin.com/company/gvrp

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GV Research Platform